Test ID MFRGP Marfan Syndrome and Related Disorders Multi-Gene Panel, Blood
Useful For
Providing a comprehensive genetic evaluation for patients with a personal or family history suggestive of Marfan syndrome, Loeys-Dietz syndrome, thoracic aortic aneurysm and dissections, or a related disorder
Second-tier testing for patients in whom previous targeted gene variant analyses for specific Marfan and related genes were negative
Establishing a diagnosis of a Marfan or a related disorder in some cases, allowing for appropriate management and surveillance for aneurysms and other disease features based on the gene involved
Identifying variants within genes known to be associated with increased risk for aneurysms and other disease features allowing for predictive testing of at-risk family members
Special Instructions
Method Name
Custom Sequence Capture and Targeted Next Generation Sequencing followed by Polymerase Chain Reaction (PCR) and Supplemental Sanger Sequencing
Reporting Name
Marfan and Related Genetic Panel, BSpecimen Type
Whole Blood EDTAContainer/Tube: Lavender top (EDTA)
Specimen Volume: 3 mL
Collection Instructions: Send specimen in original tube.
Additional Information:
1. Include physician name and phone number with the specimen.
2. Prior Authorization is available for this test. Submit the required form with the specimen.
Forms:
1. Marfan and Related Disorders Patient Information (T636) in Special Instructions
2. New York Clients-Informed consent is required. Please document on the request form or electronic order that a copy is on file. An Informed Consent for Genetic Testing (T576) is available in Special Instructions.
3. Marfan Syndrome and Related Disorders Multi-Gene Panel Prior Authorization Ordering Instructions in Special Instructions
4. If not ordering electronically, complete, print, and send a Cardiovascular Test Request Form (T724) with the specimen (http://www.mayomedicallaboratories.com/it-mmfiles/cardiovascular-request-form.pdf).
Specimen Minimum Volume
0.6 mL
Specimen Stability Information
Specimen Type | Temperature | Time |
---|---|---|
Whole Blood EDTA | Ambient (preferred) | |
Refrigerated |
Clinical Information
Marfan syndrome (MFS) is an autosomal dominant genetic disorder affecting the connective tissue that occurs in approximately 1 to 2 per 10,000 individuals. It is characterized by the presence of skeletal, ocular, and cardiovascular manifestations and is caused by variants in the FBN1 gene. Skeletal findings may include tall stature, chest wall deformity, scoliosis, and joint hypermobility. Lens dislocation (ectopia lentis) is the cardinal ocular feature, and mitral valve prolapse and aortic root dilatation/dissection are the main cardiovascular features. Diagnosis is based on the revised Ghent nosology and genetic testing of FBN1. Management aims to monitor and slow the rate of aortic root dilatation, and initiate appropriate medical and/or surgical intervention as needed. Other phenotypes associated with the FBN1 gene include autosomal dominant ectopia lentis (displacement of the lens of the eye), thoracic aortic aneurysm and dissections (TAAD), isolated skeletal features of MFS, MASS phenotype (mitral valve prolapse, aortic diameter increased, stretch marks, skeletal features of MFS), Shprintzen-Goldberg syndrome (Marfanoid-craniosynostosis; premature ossification and closure of sutures of the skull), and autosomal dominant Weill-Marchesani syndrome (short stature, short fingers, ectopia lentis).
Loeys-Dietz syndrome (LDS) is an autosomal dominant connective tissue disease with significant overlap with Marfan syndrome, but may include involvement of other organ systems and is primarily caused by variants in TGFBR1 and TGFBR2. Features of LDS that are not typical of MFS include craniofacial and neurodevelopmental abnormalities, and arterial tortuosity with increased risk for aneurysm and dissection throughout the arterial tree. Variants of the SMAD3 gene have been reported in families with a LDS-like phenotype with arterial aneurysms and tortuosity and early onset osteoarthritis.
TAAD is a genetic condition primarily involving dilatation and dissection of the thoracic aorta, but may also include aneurysm and dissection of other arteries. TAAD has a highly variable age of onset and presentation, and may involve additional features such as congenital heart defects and other features of connective tissue disease or smooth muscle abnormalities depending on the causative gene. The gene most commonly involved in familial TAAD is ACTA2, followed by TGFBR1 and TGFBR2, and MYH11. Variants in the MYLK gene have been reported in a small subset of families with familial TAAD. TGFB2 variants have also been reported in families with TAAD and systemic features that overlap with LDS and MFS.
The COL3A1 gene causes Ehlers Danlos syndrome type IV (vascular type), an autosomal dominant connective tissue disease with characteristic facial features, thin, translucent skin, easy bruising, and arterial, intestinal, and uterine fragility. Arterial rupture may be preceded by aneurysm or dissection, or may occur spontaneously.
Autosomal dominant variants of the FBN2 gene are known to cause congenital contractural arachnodactyly (CCA), which has several overlapping features with Marfan syndrome, including dolichostenomelia, scoliosis, pectus deformity, arachnodactyly, and a risk for thoracic aortic aneurysm.
Variants of the CBS gene cause homocystinuria an autosomal recessive disorder of amino acid metabolism with clinical overlap with Marfan syndrome; including lens dislocation and skeletal abnormalities, as well as increased risk for abnormal blood clotting.
Mutations in the SKI gene cause Shprintzen-Goldberg syndrome (SGS), an autosomal dominant condition with overlap with LDS and MFS. Distinguishing features of SGS include hypotonia and intellectual disability. Aortic root dilatation is less frequent in SGS than in LDS or MFS, but, when present, it can be severe.
Homozygous and compound heterozygous loss of function variants in the SLC2A10 gene have been described in arterial tortuosity syndrome, a condition characterized by generalized tortuosity and elongation of all major arteries in addition to other connective tissue disease features.
Genes included in Marfan Syndrome and Related Disorders Multi-Gene Panel:
Gene |
Protein |
Inheritance |
Known Association |
ACTA2 |
Actin, alpha-2, smooth muscle, aorta |
AD |
TAAD |
CBS |
Cystathionine beta-synthase |
AR |
Homocystinuria |
COL3A1 |
Collagen, type III, alpha-1 |
AD |
Ehlers-Danlos syndrome Type IV (vascular type) |
FBN1 |
Fibrillin 1 |
AD |
Marfan syndrome/TAAD/Ectopia Lentis/ MASS phenotype/Shprintzen-Goldberg syndrome/Weill-Marchesani syndrome |
FBN2 |
Fibrillin 2 |
AD |
Congenital Contractural Arachnodactyly |
MYH11 |
Myosin, heavy chain 11, smooth muscle |
AD |
TAAD |
MYLK |
Myosin light chain kinase |
AD |
TAAD |
SKI |
V-SKI avian sarcoma viral oncogene homolog |
AD |
Shprintzen-Goldberg syndrome |
SLC2A10 |
Solute carrier family 2 (facilitated glucose transporter), member 10 |
AR |
Arterial Tortuosity syndrome/TAAD (Autosomal Recessive) |
SMAD3 |
Mothers against decapentaplegic, drosophila, homolog of, 3 |
AD |
Loeys-Dietz syndrome/TAAD |
TGFB2 |
Transforming growth factor, beta-2 |
AD |
TAAD |
TGFBR1 |
Transforming growth factor-beta receptor, type I |
AD |
Loeys-Dietz syndrome/TAAD |
TGFBR2 |
Transforming growth factor-beta receptor, type II |
AD |
Loeys-Dietz syndrome/TAAD |
Abbreviations: Autosomal dominant (AD), autosomal recessive (AR)
Indications for testing include but are not limited to:
-Patients who meet clinical diagnostic criteria (Revised Ghent nosology) for Marfan syndrome
-Patients in whom no specific Marfan or related disorder is evident but for whom there is a clear familial component
-Patients whose family history is consistent with TAAD
-Patients with a personal or family history of thoracic aortic aneurysm and/or dissection or a personal or family history of multiple arterial aneurysms
Reference Values
An interpretive report will be provided.
Cautions
Clinical Correlations:
Some individuals who have involvement of 1 or more of the genes on the panel may have a variant that is not identified by the methods performed (eg, promoter variants, deep intronic variants). The absence of a variant, therefore, does not eliminate the possibility of Marfan syndrome or a related disorder.
Test results should be interpreted in context of clinical findings, family history, and other laboratory data. Misinterpretation of results may occur if the information provided is inaccurate or incomplete.
If testing was performed because of a family history of Marfan syndrome or a related disorder, it is often useful to first test an affected family member. Identification of a pathogenic variant in an affected individual would allow for more informative testing of at risk individuals.
Technical Limitations:
Next generation sequencing may not detect all types of genetic variants. Additionally, rare polymorphisms may be present that could lead to false negative or positive results. If results do not match clinical findings, consider alternative methods for analyzing these genes, such as Sanger sequencing or large deletion/duplication analysis. If the patient has had an allogeneic blood or marrow transplant or a recent (ie, less than 6 weeks from time of sample collection) heterologous blood transfusion these results may be inaccurate due to the presence of donor DNA.
Reclassification of Variants Policy:
At this time, it is not standard practice for the laboratory to systematically review likely pathogenic variants or variants of uncertain significance that are detected and reported. The laboratory encourages health care providers to contact the laboratory at any time to learn how the status of a particular variant may have changed over time.
Contact the laboratory if additional information is required regarding the transcript and/or human genome assembly used for the analysis of this patient’s results.
Day(s) Performed
Wednesday; Varies
Report Available
4 weeks after prior authorization approvedPerforming Laboratory

Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.CPT Code Information
81410
NY State Approved
ConditionalPrior Authorization
Insurance preauthorization is available for this testing; forms are available in Special Instructions.
Patient financial assistance may be available to those who qualify. Patients who receive a bill from Mayo Medical Laboratories will receive information on eligibility and how to apply.